Protocol Ledger

NCT07402551 · Phase II · RECRUITING

Phase II Study of RC1416 Injection in COPD

Interventional Phase II clinical trial protocol NCT07402551 sponsored by Nanjing RegeneCore Biotech Co in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-03-06 Enrollment: 180 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07402551
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)180 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07402551
Protocol FieldVerified Registry Value
NCT IdentifierNCT07402551
Consolidated Lead SponsorNanjing RegeneCore Biotech Co
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment180 participants (ESTIMATED)
Registered Start Date2026-03-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07402551
Hospital Research SiteLocationSite Profile
The First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, ChinaOpen Hospital Dossier ->
The first affiliated hospital of Guangxi Medical UniversityNanning, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI